Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| EUPAS1000000076 | Other Identifier | HMA-EMA RWD Catalogues | |
| CHIL 62837 | Other Identifier | NIHR CPMS | |
| 334976 | Other Identifier | HRA IRAS |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| OXON Epidemiology | INDUSTRY |
Not provided
Not provided
Not provided
This post-authorisation safety and efficacy study (PRECISE PASS) evaluates the use of Xromi® (hydroxycarbamide 100 mg/mL oral solution) in children aged 9 months to under 2 years with sickle cell disease (SCD).
The objective is to assess the safety profile and clinical effectiveness of Xromi® under routine clinical conditions. The study includes a prospective cohort of Xromi®-treated patients and a matched retrospective comparator cohort of untreated patients. Participants will be followed for 24 months from treatment initiation or matched index date.
The PRECISE study is a combined Post-Authorisation Safety Study (PASS) (Category 3) and a Post-Authorisation Efficacy Study that aims to provide data on the safety and effectiveness of hydroxycarbamide 100mg/ml oral solution (Xromi ®) administered prospectively to children under 2 years of age, over a follow-up period of 24 months compared to matched retrospective comparators who were treatment naïve.
This is a non-interventional, matched cohort study involving children with SCD aged 9 to under 24 months. The study comprises two groups:
The primary objective is to compare the incidence of adverse events of special interest (AESIs) between the two cohorts. Secondary analyses will assess the comparative effectiveness of Xromi® on clinical events, laboratory parameters, and physiological assessments. Exploratory analyses will examine treatment-related safety and effectiveness by dose, subgroups, and exposure to hydroxycarbamide during follow-up.
Data will be sourced from routine clinical practice through chart reviews and follow-up visits. No study-specific interventions will be introduced. The study is planned across specialist sites in the UK and Germany, with potential expansion to other European countries if recruitment targets require.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Prospective Exposure Cohort | Children with SCD aged 9 months to under 2 years of age who are newly prescribed Xromi®, will be identified prospectively. These participants will be followed up for 24 months from their index date, regardless of whether they continue treatment with Xromi®, discontinue all hydroxycarbamide treatment, or switch to another formulation of hydroxycarbamide. The decision to prescribe Xromi® will be made solely by the physician independently of the study, as part of standard care. - |
| |
| Retrospective Comparator Cohort | Children with SCD and naïve to any hydroxycarbamide formulation at the index date. These participants will be identified retrospectively using the data from the last 10 years up to the date Xromi® was first used in children from 9 months to under 2 years of age at each individual site. The 24-month follow-up will be retrospective from the date they are matched to the exposed participant, irrespective of whether they start on any formulation of hydroxycarbamide during the follow-up. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Xromi | Drug | Xromi is indicated for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age as part of standard clinical practice |
|
| Measure | Description | Time Frame |
|---|---|---|
| AESI - Myelosuppression (Neutropenia) | Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort. Myelosuppression protocol definition of neutropenia is ANC <1.0 x 10^9/L | Pre-baseline, Baseline to 24 months |
| AESI - Myelosuppression (Reticulocytopenia) | Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort. Myelosuppression protocol definition of reticulocytopenia is ARC <80 x 10^9/L, unless Hb >90 g/L, | Pre-baseline, Baseline to 24 months |
| AESI - Myelosuppression (Thrombocytopenia) | Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort. Myelosuppression protocol definition of thrombocytopenia defined as platelets <80 x 10^9/L. | Pre-baseline, Baseline to 24 months |
| AESI - Myelosuppression (Anaemia) | Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort. Myelosuppression protocol definition of anaemia defined as Hb <45 g/L. | Pre-baseline, Baseline to 24 months |
| AESI - Abnormal Weight Gain | Weight (kg) Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort and standard care guidelines | Baseline to 24 months |
| AESI - Abnormal Weight Loss |
| Measure | Description | Time Frame |
|---|---|---|
| Other Adverse Events | Occurrence of other adverse events (AE), adverse reactions (AR) and serious adverse events (SAE) or serious adverse reactions (SAR) will be collected during follow-up. | Baseline to 24 months |
| Painful Vaso-occlusive Crisis (VOC) |
Not provided
Prospective Exposure Cohort
Inclusion criteria:
Exclusion criteria:
Participants in the prospective exposure cohort who are prescribed Xromi® but do not initiate treatment will be excluded from the dataset.
Retrospective Comparator cohort
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
The study population will consist of children with SCD who meet all the inclusion criteria and none of the exclusion criteria.
Identification of participants will be conducted as follows:
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hussain Mulla, PhD | Contact | +44 (0)116 223 0100 | hussain.mulla@novalabs.co.uk | |
| Sarah Edwards, PhD | Contact | +44 (0)116 223 0100 | sarah.edwards@novalabs.co.uk |
| Name | Affiliation | Role |
|---|---|---|
| Hussain Dr Mulla, PhD | Nova Laboratories Ltd. | Study Director |
| Sara Dr Trompeter, MD | University College London Hospitals | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universitätsklinikum Hamburg-Eppendorf | Recruiting | Hamburg | Germany | |||
| Universitätsklinikum Heidelberg |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37171600 | Background | Rankine-Mullings A, Keenan R, Chakravorty S, Inusa B, Telfer P, Velangi M, Ware RE, Moss JJ, Lloyd AL, Edwards S, Mulla H. Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia. Blood Adv. 2023 Aug 22;7(16):4319-4322. doi: 10.1182/bloodadvances.2023010099. No abstract available. | |
| 19731330 |
Not provided
Not provided
The study has been registered on a public database HMA-EMA RWD Catalogues and the study protocol has been shared publicly (EUPAS1000000076).
Study publication of aggregated outcome results on Clinical trials.gov and in Multi-centre study publication in relevant medical journal.
Investigators:
All Investigators will be provided with their individual participant data at the end of the study as eCRFs.
Regulatory Authorities:
The study protocol was shared with the EMA and MHRA. The draft SAP was shared with the EMA during initial review of the study protocol prior to study initiation.
CSR will be made available to the EMA and MHRA at the end of the study.
March 2025 - upto 25 years from end of study.
Publicly accessible study protocol via the HMA-EMA RWD Catalogues and the study protocol has been shared publicly (EUPAS1000000076) Publicly accessible aggregated study results via ClinicalTrials.Gov.
Not provided
Not provided
Not provided
Not provided
Not provided
|
Weight (kg) Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort and standard care guidelines |
| Baseline to 24 months |
| AESI - Increase in Hepatic Enzyme (ALT) | Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort and normal laboratory ranges. Defined as an increase in hepatic enzyme Alanine transaminase (ALT) increased (U/L) | Baseline to 24 months |
| AESI - Increase in Hepatic Enzyme (AST) | Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort and normal laboratory ranges. Defined as an increase in hepatic enzyme Aspartate transaminase (AST) increased (U/L) | Baseline to 24 months |
| AESI - Alopecia | Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort. Defined in study protocol as presence of alopecia (a skin and subcutaneous tissue disorder). | Pre-baseline, Baseline to 24 months |
| AESI - Other Hair Loss | Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort. Defined in study protocol as presence of other hair loss (a skin and subcutaneous tissue disorder). | Pre-baseline, Baseline to 24 months |
| AESI - Skin Hyperpigmentation | Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort. Defined in study protocol as presence of skin hyperpigmentation, including oral and nail hyperpigmentation.(a skin and subcutaneous tissue disorder). | Pre-baseline, Baseline to 24 months |
| AESI - Rash | Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort. Defined in study protocol as presence of a rash (a skin and subcutaneous tissue disorder). | Pre-baseline, Baseline to 24 months |
| AESI - Skin Ulcers | Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort. Defined in study protocol as presence of skin ulcer, including leg ulcer (a skin and subcutaneous tissue disorder). | Pre-baseline, Baseline to 24 months |
| AESI - Growth Retardation | height/length (cm) Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort and standard care guidelines (as a drop of 2 or more centiles on growth charts over time). | Pre-baseline, Baseline to 24 months |
| AESI - Bacterial Infection | Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort. Defined in the protocol as a proven or treated bacterial infection. | Pre-baseline, Baseline to 24 months |
| AESI - Viral Infection | Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort. Defined in the protocol as a proven or treated viral infection. | Pre-baseline, Baseline to 24 months |
| AESI - Fungal Infection | Incidence of adverse events of special interest (AESIs) in children who have SCD and are treated with Xromi®, in comparison to a retrospective comparator cohort. Defined in the protocol as a proven or treated fungal infection. | Pre-baseline, Baseline to 24 months |
Occurrence of the clinical event will be collected during follow-up in both cohorts by the investigator to compare the Effectiveness of Xromi®.
- VOC events will include dactylitis.
| Pre-baseline, Baseline to 24 months |
| Acute Chest Syndrome (ACS) | Occurrence of the clinical event will be collected during follow-up in both cohorts by the investigator to compare the Effectiveness of Xromi®. | Pre-baseline, Baseline to 24 months |
| Splenomegaly | Occurrence of the clinical event Splenomegaly will be collected during follow-up in both cohorts by the investigator to compare the Effectiveness of Xromi®. | Pre-baseline, Baseline to 24 months |
| Priapism | Occurrence of the clinical event will be collected during follow-up in both cohorts by the investigator to compare the Effectiveness of Xromi®. | Baseline to 24 months |
| Hepatobiliary disorder | Occurrence of the clinical event will be collected during follow-up in both cohorts by the investigator to compare the Effectiveness of Xromi®. | Pre-baseline, Baseline to 24 months |
| Splenic Sequestration Crisis | Occurrence of the clinical event will be collected during follow-up in both cohorts by the investigator to compare the Effectiveness of Xromi®. | Pre-baseline, Baseline to 24 months |
| Surgery | Occurrence of the clinical event will be collected during follow-up in both cohorts by the investigator to compare the Effectiveness of Xromi®. Defined in the protocol as any surgery that is planned, emergency, or due to pre-existing conditions e.g. SCD. | Pre-baseline, Baseline to 24 months |
| Blood Transfusion | Occurrence of the clinical event will be collected during follow-up in both cohorts by the investigator to compare the Effectiveness of Xromi®. | Pre-baseline, Baseline to 24 months |
| Cerebrovascular accident | Occurrence of the clinical event will be collected during follow-up in both cohorts by the investigator to compare the Effectiveness of Xromi®. The protocol definition includes silent stroke | Pre-baseline, Baseline to 24 months |
| Abnormal or Conditional TCD | Occurrence of the clinical event will be collected during follow-up in both cohorts by the investigator to compare the Effectiveness of Xromi®. - Transcranial Doppler Scan (TCD) | Pre-baseline, Baseline to 24 months |
| Hospitalisations for SCD | Occurrence of the clinical event will be collected during follow-up in both cohorts by the investigator to compare the Effectiveness of Xromi®. The reason for hospitalisation and duration will be collected. | Pre-baseline, Baseline to 24 months |
| Non-hospitalised Visit for SCD | Occurrence of the clinical event will be collected during follow-up in both cohorts by the investigator to compare the Effectiveness of Xromi®. Protocol definition includes Emergency department (ED) visits/treatment centres/paediatric ward/day unit attendances for SCD | Pre-baseline, Baseline to 24 months |
| Other Clinical Events | Occurrence of the clinical event will be collected during follow-up in both cohorts by the investigator to compare the Effectiveness of Xromi®. | Pre-baseline, Baseline to 24 months |
| Other Event - Death | Occurrence of the clinical event will be collected during follow-up in both cohorts by the investigator. Protocol definition includes any death occurring in the study both related and un-related to Xromi treatment | Baseline to 24 months |
| Haemoglobin (Hb) | (g/L) or (g/dl) Haematological Parameter. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Foetal Haemoglobin (HbF) | (%) Haematological Parameter. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Haemoglobin Fractions | (%) Haematological Parameter. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. - Haemoglobinopathy screen results including: HbS, HbA, HbA2, HbC | Pre-baseline, Baseline to 24 months |
| Absolute Neutrophil Count (ANC) | (10^9/L or /nL) Haematological Parameter. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Absolute Reticulocyte Count (ARC) | (10^9/L or /nL) Haematological Parameter. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Platelet Count | (10^9/L or /nL) Haematological Parameter. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| White Blood Cell Count (WBC) | (10^9/L or /nL) Haematological Parameter. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Mean Corpuscular Volume (MCV) | (fl) Haematological Parameter. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Mean Corpuscular Haemoglobin (MCH) | (pg) Haematological Parameter. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Ferritin | (µg/L) Iron Profile. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Transferrin Saturation | (%) Iron Profile. Iron binding saturation or transferrin saturation. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Alanine Transaminase (ALT) | (U/L) Liver Function tests. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Alkaline Phosphatase (ALP) | (U/L) Liver Function tests. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Aspartate Transaminase (AST) | (U/L) Liver Function tests. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Total Bilirubin | (µmol/L or mg/dl) Liver Function tests. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Lactate Dehydrogenase | (U/L) Liver Function tests. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Gamma-Glutamyl Transferase (GGT) | (U/L) Liver Function tests. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Serum Creatinine | (µmol/L or mg/dl) Renal function test. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Estimated Glomular Filtration Rate (eGFR) | (ml/min/1.73m^2) Renal function test. Calculated value, Interpreted in line with UK CKD guidelines from creatinine values. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Albumin-Creatinine Ratio (ACR) | (Calculated value). Renal function test. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Liver Size | (cm) from costal margin. Physiological Assessment. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Spleen Size | (cm) from costal margin. Physiological Assessment. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Maximum Time Averaged Mean Velocity (TAMV) | (cm/s) Cardiovascular function, assessed using transcranial doppler scan velocities. Results and dates of laboratory tests and physiological assessments will be collected, whenever available. At baseline, the most recent results, prior to Xromi® initiation in the prospective exposure cohort, will be collected. Results from laboratory tests and physiological assessments conducted during follow-up will also be collected. | Pre-baseline, Baseline to 24 months |
| Recruiting |
| Heidelberg |
| Germany |
| Basildon University Hospital | Recruiting | Basildon | United Kingdom |
| Noah's Ark Children's Hospital for Wales | Recruiting | Cardiff | United Kingdom |
| Evelina London Children's Hospital | Recruiting | London | United Kingdom |
| Kings College Hospital | Recruiting | London | United Kingdom |
| North Middlesex University Hospital | Recruiting | London | United Kingdom |
| The Royal London Hospital | Recruiting | London | United Kingdom |
| University College London Hospital | Recruiting | London | United Kingdom |
| Whittington Hospital | Recruiting | London | United Kingdom |
| Royal Manchester Children's Hospital | Recruiting | Manchester | United Kingdom |
| John Radcliffe Hospital | Recruiting | Oxford | United Kingdom |
| Thompson BW, Miller ST, Rogers ZR, Rees RC, Ware RE, Waclawiw MA, Iyer RV, Casella JF, Luchtman-Jones L, Rana S, Thornburg CD, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik S, Howard TH, Luck L, Wang WC. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer. 2010 Feb;54(2):250-5. doi: 10.1002/pbc.22269. |
| ID | Term |
|---|---|
| D000755 | Anemia, Sickle Cell |
| D006453 | Hemoglobinopathies |
| ID | Term |
|---|---|
| D000745 | Anemia, Hemolytic, Congenital |
| D000743 | Anemia, Hemolytic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided
| ID | Term |
|---|---|
| D006918 | Hydroxyurea |
| ID | Term |
|---|---|
| D014508 | Urea |
| D000577 | Amides |
| D009930 | Organic Chemicals |
Not provided
Not provided